• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    GeminiBio Appoints Industry Veteran Cory Stevenson as Executive Chairman

    3/16/23 5:00:00 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials
    Get the next $TMO alert in real time by email

    FORT LAUDERDALE, Fla. and Sacramento, Calif., March 16, 2023 /PRNewswire/ -- Gemini BioProducts Holding, Inc. ("GeminiBio" or the "Company"), a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Florida-based healthcare private equity firm, announced the appointment of Cory Stevenson as Executive Chairman of the Board of Directors.

    (PRNewsfoto/BelHealth Investment Partners)

    GeminiBio Appoints Industry Veteran Cory Stevenson as Executive Chairman

    Mr. Stevenson joined the Board of GeminiBio in 2022 and has been working closely with the GeminiBio management team as they prepare to complete a three-phase buildout that addresses the long-term capacity needs in the biopharma and cell/gene therapy marketplace. Previously, Mr. Stevenson served as President of the BioProduction Division of Thermo Fisher Scientific (NYSE:TMO), a world leader in serving the biopharma sector, with annual revenue of more than $40 billion. During Cory's tenure, the BioProduction business grew from $200 million in revenues to over $2.5 billion annually.

    Harold S. Blue, Managing Partner of BelHealth Investment Partners said, "We are fortunate to have Cory expand his role and guide our strategy at GeminiBio. Cory has been very helpful during the last year as a board member and I am excited that he will be taking a more active role. Also, given that Cory worked directly with GeminiBio's CEO, Brian Parker, while at Thermo Fisher, this was a natural fit."

    Cory Stevenson, Executive Chairman of GeminiBio added, "I am delighted to expand my role at GeminiBio after working closely with Brian and the rest of the team since I joined the Board. With the completion of its 57,000-square-foot manufacturing facilities, GeminiBio is positioning itself as a vendor delivering much-needed critical solutions to the global biopharma industry. I am looking forward to this exciting next phase at GeminiBio."

    About BelHealth Investment Partners

    BelHealth Investment Partners, based in Fort Lauderdale, Florida, is a healthcare private equity firm focused on lower middle market companies. BelHealth has a unique combination of investing, executive management, and entrepreneurial experience. BelHealth acquires majority positions in entrepreneur-owned companies that it believes will benefit from its extensive operating and private equity investment expertise. For more information, visit www.belhealth.com.

    About GeminiBio

    Founded in 1985, GeminiBio serves the global biotechnology industry, from basic research to commercial production, with a focus on helping our customers accelerate the development of life enhancing biotherapeutics by streamlining and improving their cell culture and process liquid manufacturing workflows. The company's products are organized into two core verticals – Cell Culture Solutions and Process Liquid Solutions. Located in West Sacramento, California, GeminiBio has 57,000 square feet of cGMP manufacturing space that is segregated between animal origin free and animal component manufacturing. GeminiBio is an ISO 13485 certified, FDA registered Class 1 Medical Device Manufacturer, aligned with 21 CFR Part 820. For more information, visit www.geminibio.com.

    Contact:

    BelHealth: Inder Tallur, [email protected]

    GeminiBio: [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/geminibio-appoints-industry-veteran-cory-stevenson-as-executive-chairman-301774586.html

    SOURCE BelHealth Investment Partners

    Get the next $TMO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TMO

    DatePrice TargetRatingAnalyst
    1/10/2025$630.00Mkt Perform → Outperform
    Bernstein
    12/23/2024Sector Perform
    Scotiabank
    10/14/2024Buy
    Redburn Atlantic
    10/1/2024$680.00Overweight
    Stephens
    8/28/2024$670.00Overweight
    Wells Fargo
    6/3/2024$650.00Buy
    Jefferies
    3/18/2024$620.00Neutral
    Citigroup
    1/24/2024$475.00 → $555.00Overweight → Equal Weight
    Barclays
    More analyst ratings

    $TMO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Thermo Fisher upgraded by Bernstein with a new price target

      Bernstein upgraded Thermo Fisher from Mkt Perform to Outperform and set a new price target of $630.00

      1/10/25 8:42:46 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • Scotiabank initiated coverage on Thermo Fisher

      Scotiabank initiated coverage of Thermo Fisher with a rating of Sector Perform

      12/23/24 8:24:48 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • Redburn Atlantic initiated coverage on Thermo Fisher

      Redburn Atlantic initiated coverage of Thermo Fisher with a rating of Buy

      10/14/24 9:24:58 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials

    $TMO
    SEC Filings

    See more
    • SEC Form 10-Q filed by Thermo Fisher Scientific Inc

      10-Q - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)

      5/2/25 10:04:18 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • Thermo Fisher Scientific Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)

      4/23/25 6:04:04 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • SEC Form DEFA14A filed by Thermo Fisher Scientific Inc

      DEFA14A - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)

      4/8/25 7:33:36 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials

    $TMO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Thermo Fisher Scientific to Present at BofA Securities 2025 Health Care Conference on May 13

      Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the BofA Securities Health Care Conference on Tuesday, May 13, 2025 at 11:40 a.m. (ET). The live webcast of the presentation can be accessed via the Investors section of our website, www.thermofisher.com. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical

      5/6/25 8:00:00 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • Thermo Fisher Scientific Invests to Enhance U.S. Innovation and Support Customers' Manufacturing

      Investment demonstrates confidence in America's commitment to science and innovation Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, will invest an additional $2 billion in the United States over the next four years, strengthening American innovation, manufacturing and economic competitiveness across the life sciences sector. As one of the largest manufacturers of medicines in the world, Thermo Fisher enables biopharma companies to develop and produce their medicines in America. These additional investments to the company's American manufacturing capacity support a resilient U.S. healthcare supply chain and will have a strong multiplier effect across the Ame

      4/24/25 8:00:00 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • Thermo Fisher Scientific Reports First Quarter 2025 Results

      Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 29, 2025. First Quarter Highlights First quarter revenue was $10.36 billion. First quarter GAAP diluted earnings per share (EPS) grew 15% to $3.98. First quarter adjusted EPS grew 1% to $5.15. Delivered very strong financial performance in the quarter, demonstrating the strength of our trusted partner status and the power of our PPI Business System in a more uncertain macroeconomic environment. Advanced our proven growth strategy, launching a range of high-impact, innovative new products during the quarter. To transform semiconduc

      4/23/25 6:00:00 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials

    $TMO
    Leadership Updates

    Live Leadership Updates

    See more
    • GeminiBio Appoints Mike Stella to Board

      Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

      2/18/25 9:00:00 AM ET
      $AMGN
      $GSK
      $JNJ
      $MRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Industrial Machinery/Components
    • Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company's Proposed Merger with Standard BioTools

      Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4

      12/12/23 5:31:00 PM ET
      $EXAS
      $ILMN
      $LAB
      $ME
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • ViroCell Expands Business Development Team to Support Next Phase of Growth

      Traci Kyes and Makis Sigalas bring extensive industry experience to roles focused on expanding ViroCell's business in the US and Europe Team ViroCell will be attending the Cell & Gene Therapy Meeting on the Mesa, 10-12 October 2023 ViroCell Biologics ("ViroCell" or the "Company"), a specialist contract development and manufacturing organisation ("CDMO") in cell and gene therapy clinical trials, announces the appointment of Traci Kyes as Vice President (VP) of Business Development (US) and Makis Sigalas as Senior Business Development Director (Europe). Focused on driving growth in the US and Europe, respectively, Traci and Makis bring a wealth of business development expertise to ViroCel

      10/4/23 2:00:00 AM ET
      $CTLT
      $TMO
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Machinery/Components
      Industrials

    $TMO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Chai Nelson sold $8,449 worth of shares (16 units at $528.09) and bought $11,038 worth of shares (20 units at $551.90), increasing direct ownership by 0.03% to 14,252 units (SEC Form 4)

      4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

      2/21/25 4:19:32 PM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • Boxer Michael A bought $2,105 worth of shares (4 units at $526.15), increasing direct ownership by 0.03% to 13,101 units (SEC Form 4)

      4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

      10/6/23 4:23:51 PM ET
      $TMO
      Industrial Machinery/Components
      Industrials

    $TMO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Executive Vice President Pettiti Gianluca sold $128,979 worth of shares (300 units at $429.93), decreasing direct ownership by 1% to 23,167 units (SEC Form 4)

      4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

      4/30/25 4:18:02 PM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • SEC Form 4 filed by Director Weisler Dion J

      4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

      4/1/25 5:16:28 PM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • SEC Form 4 filed by Director Sperling Scott M

      4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

      4/1/25 5:15:03 PM ET
      $TMO
      Industrial Machinery/Components
      Industrials

    $TMO
    Financials

    Live finance-specific insights

    See more
    • Thermo Fisher Scientific Reports First Quarter 2025 Results

      Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 29, 2025. First Quarter Highlights First quarter revenue was $10.36 billion. First quarter GAAP diluted earnings per share (EPS) grew 15% to $3.98. First quarter adjusted EPS grew 1% to $5.15. Delivered very strong financial performance in the quarter, demonstrating the strength of our trusted partner status and the power of our PPI Business System in a more uncertain macroeconomic environment. Advanced our proven growth strategy, launching a range of high-impact, innovative new products during the quarter. To transform semiconduc

      4/23/25 6:00:00 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, April 23, 2025

      Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, announced that it will release its financial results for the first quarter 2025 before the market opens on Wednesday, April 23, 2025, and will hold a conference call on the same day at 8:30 a.m. ET. During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (833) 470-1428 within the U.S. or (404) 975-4839 outside the U.S. The access code is 074131. You may also listen to the call live on the "Investors" section of our website, www.thermofisher.com. The earnings press release and related information can also be found in that section of our website under th

      4/1/25 8:00:00 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • Thermo Fisher Scientific Increases Quarterly Dividend

      Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.43 per common share, payable on April 15, 2025, to shareholders of record as of March 14, 2025. This reflects an 10% increase over the previous dividend payment of $0.39. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their

      2/19/25 4:15:00 PM ET
      $TMO
      Industrial Machinery/Components
      Industrials

    $TMO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Thermo Fisher Scientific Inc (Amendment)

      SC 13G/A - THERMO FISHER SCIENTIFIC INC. (0000097745) (Subject)

      2/9/23 11:35:13 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • SEC Form SC 13G/A filed

      SC 13G/A - THERMO FISHER SCIENTIFIC INC. (0000097745) (Subject)

      2/10/21 11:57:23 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials